Next-generation peptides
Next-generation peptides
Lose up to 40% of body weight per year without muscle loss and with maximum energy retention
Diets and exercise don't deliver lasting results
Constant hunger and cravings
Muscle loss and low energy while losing weight
Slow metabolism and weight regain
Up to 40% weight loss per year — 3x more than semaglutide
Muscle is preserved, body becomes toned
Stable energy, focus, and great well-being
Appetite and cravings under control — without exhausting diets
~10-15%
weight loss per year
Up to 40%
weight loss per year
“Lost 22 kg in 6 months. No appetite at all, I have to force myself to eat. Body is toned, muscle is intact. This is the best thing I've tried!”-22 kg in 6 months
“With Retatrutide I lost 22 kg in 4 months. Sure, I train too, but my energy actually went up even though I'm eating less. I feel great, it cuts really well.”
SPECIAL OFFER
If you don't see results — we'll refund your money within 30 days. No questions asked.
“About 2-3 kg a month on average, I got toned, the swelling went away, there's this lightness now. I've been using it for six months. Definitely recommend.”-2-3 kg/month
Retatrutide (LY3437943) is a synthetic peptide, a triple agonist of the GIP, GLP-1, and glucagon receptors — a new generation beyond mono- and dual agonists. The molecule is still investigational, under clinical study. This material is supplied strictly for laboratory and research purposes, not for human use.
Yes, the material is supplied as a laboratory/research reagent (research use only) and is not a medicinal product. It is not intended for diagnosis, treatment, or use in humans or animals. Compliance with local rules on handling research reagents is the buyer's responsibility.
Retatrutide is a triple agonist of GIP/GLP-1/glucagon, while semaglutide acts only on the GLP-1 receptor. Thanks to its additional targets, retatrutide shows weight loss of up to 40% per year — roughly 3x more than the ~10-15% seen with semaglutide. This is clinical-trial data; retatrutide is still investigational.
Dosing depends on the study protocol. The published Phase 2 trial (Jastreboff et al., NEJM 2023) used weekly subcutaneous injections with dose escalation: starting at 2 mg, increased every 4 weeks to a target dose of 4, 8, or 12 mg, maintained through week 48. The lyophilizate is reconstituted with sterile bacteriostatic water to a concentration set by the specific study protocol — the exact solvent volume depends on the desired concentration. This describes the methodology of a published study, not instructions for self-administration.
Store the lyophilized powder in a dry, cool place away from light; for long-term storage, keep it in a freezer. After reconstitution, keep the material refrigerated and use it according to your study protocol.
We ship via Nova Poshta across Ukraine with a tracking number. Payment is on delivery or by cryptocurrency, your choice. Packaging is discreet.
A detailed monograph with study data and source references is available at /en/wiki/retatrutide. The material is for scientific reference and research purposes.
